MedTrace Logo

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

NCT05146687 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 369600

Last updated 2021-12-16

No results posted yet for this study

Summary

This was the cross-sectional study to assess the period prevalence of IOI in patients with wet AMD who were treated with anti- VEGF agents (excluding brolucizumab) over a one-year period in 2019.

Conditions

  • Age-related Macular Degeneration (AMD)

Interventions

OTHER

Aflibercept

intravitreal injection

OTHER

Ranibizumab

intravitreal injection

OTHER

Bevacizumab

intravitreal injection

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2020-12-11
Completion
2020-12-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05146687 on ClinicalTrials.gov